Objective:To investigate the clinical efficacy of haploidentical high-dose in vitro non-T-cell-depleted peripheral blood hematopoietic stem cell transplantation (haplo-HDPSCT) in treating adult patients with Ph + acute lymphoblastic leukemia (Ph + ALL) . Method:This retrospective analysis was conducted on the clinical efficacy of 25 adult patients with Ph + ALL who underwent haplo-HDPSCT from July 2011 to June 2022 at our hospital. Results:This study included 25 patients with a median age of 27 (16-61) years, consisting of 12 males and 13 females. CR1 and ≥CR2 before transplantation were found in 23 and 2 cases, positive and negative minimal residual lesions were observed in 8 and 17 cases, and myeloablative conditioning and reduced-intensity conditioning were reported in 21 and 4 cases, respectively. Hematopoietic function was restored in all 25 patients after stem cell infusion. Of the 25 patients who underwent transplantation, 16 developed acute graft-versus-host disease (aGVHD). The cumulative incidence rates of Ⅱ-Ⅳ and Ⅲ-Ⅳ aGVHD were (40.4±11.3) % and (4.8±4.6) %, respectively. Four patients experienced relapse after transplantation, the cumulative relapse rates at 1 and 2 years after transplantation were (4.0±3.9) % and (14.5±7.9) %, respectively. The 2-year overall survival rate after transplantation was (81.3±8.5) % and the disease-free survival rate was (77.1±9.1) %.Conclusion:This study reveals that the unique haplo-HDPSCT protocol achieves good clinical efficacy in Ph + ALL treatment.

Objective:To investigate the clinical efficacy of haploidentical high-dose in vitro non-T-cell-depleted peripheral blood hematopoietic stem cell transplantation (haplo-HDPSCT) in treating adult patients with Ph + acute lymphoblastic leukemia (Ph + ALL) . Method:This retrospective analysis was conducted on the clinical efficacy of 25 adult patients with Ph + ALL who underwent haplo-HDPSCT from July 2011 to June 2022 at our hospital. Results:This study included 25 patients with a median age of 27 (16-61) years, consisting of 12 males and 13 females. CR1 and ≥CR2 before transplantation were found in 23 and 2 cases, positive and negative minimal residual lesions were observed in 8 and 17 cases, and myeloablative conditioning and reduced-intensity conditioning were reported in 21 and 4 cases, respectively. Hematopoietic function was restored in all 25 patients after stem cell infusion. Of the 25 patients who underwent transplantation, 16 developed acute graft-versus-host disease (aGVHD). The cumulative incidence rates of Ⅱ-Ⅳ and Ⅲ-Ⅳ aGVHD were (40.4±11.3) % and (4.8±4.6) %, respectively. Four patients experienced relapse after transplantation, the cumulative relapse rates at 1 and 2 years after transplantation were (4.0±3.9) % and (14.5±7.9) %, respectively. The 2-year overall survival rate after transplantation was (81.3±8.5) % and the disease-free survival rate was (77.1±9.1) %.Conclusion:This study reveals that the unique haplo-HDPSCT protocol achieves good clinical efficacy in Ph + ALL treatment.

Objective To investigate the clinical manifestations,pathological characteristics,treatment and outcome of Castleman's disease (CD).Methods Retrospective analysis of clinical manifestations,laboratory examination,pathology and treatment of 10 patients with CD from March 2011 to May 2014 in our hospital was performed.Results 4 cases were males,6 cases were females,with a median age of 44 years (30-71 years old).1 case was unicentric Castleman's disease (UCD),9 cases were multicentric Castleman's disease (MCD).3 cases were hyaline-vascular type and 7 cases in plasma cell type according to pathological classification,non mixed type.1 UCD case with HV type acquired remission after surgery.One case of MCD did not receive chemotherapy,eight cases were received chemotherapy,including one case of complete remission,6 cases of stable disease,one case of disease progression.None of the patients were transferred into lymphoma.The median follow-up time was 26.5 months (from 13 to 64 months),1 patient died,3-year probabilities overall survival was 84.3％.Conclusion CD had various symptoms and signs.It was diagnosed by pathology.The UCD was often asymptomatic and curable by surgical excision of the mass,while MCD had a less favorable prognosis by chemotherapy and chemotherapy combined with monoclonal antibodies.

Objective To evaluated the clinical efficacy of fludarabine combined with cyclophosphamide on chronic lymphocytic leukemia and the effect on peripheral blood Th 17 and Treg cell ratio.Methods Two hundred patients were randomly divided into control group ( n=100 ) and treatment group ( n=100 ).Patients in control group intravenously given fludarabine 25 mg · m-2 on 1 -3 d; patients in treatment group were intravenously given fludarabine 25 mg · m-2 and cyclophosphamide 250 mg· m-2 on 1 -3 d.A cycle of both groups were 4 weeks, and all treated for 2 cycles.The clinical efficacy , incidence of adverse drug reactions, and the ratio of Th17 and Treg cells in peripheral blood were observed .Results The total improvement rate of treatment group was 98.0%, higher than that in control group , which was 72.0%( P<0.05).The incidence of adverse drug reactions in treatment group was 8.0%, significantly lower than 29.0% in control group (P<0.05).The Th17 cells and Treg cells in treatment group were significantly better than those in control group ( P <0.05 ) .Conclusion Fludarabine combined with cyclophosphamide had a good clinical efficiency on chronic lymphocytic leukemia , which reduced the risk of adverse reactions and can significantly improve the Th 17 and Treg cells in peripheral blood.